Melbourne-based Telix Pharmaceuticals Limited (ASX: TLX) has received some positive news with reports testing of systems to detect clear cell renal cell cancer can recommence in Europe following COVID-19 delays.
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR).
Patient recruitment for the company’s ZIRCON phase III trial of TLX250-CDx (Zr-girentuximab) has re-started at clinical sites in France with the dosing of two patients at Centre Hospitalier Universitaire (CHU) de Nantes in Nantes.
Clinical sites in Belgium and the Netherlands have also been reactivated, with patient recruitment expected to resume in the next two weeks.
Telix CEO, Dr Christian Behrenbruch, said the company expects clinical trial sites in Australia, Canada, Turkey and USA to follow between now and September, subject to conditions remaining stable.
We are relieved to be restarting patient recruitment into the ZIRCON study and gratefully acknowledge the patience and dedication of our investigators and their clinical staff during this necessary hiatus,” Dr Behrenbruch said.
“Although we had stopped patient enrolment, we had not paused recruitment and we see an encouraging patient backlog to regain momentum.”
ZIRCON (Zirconium Imaging in Renal Cancer Oncology, NCT03849118) is an international multi-centre Phase III study at up to 33 sites in Europe, Australia, Turkey, Canada and the United States.
ZIRCON is a prospective imaging trial in approximately 250 renal cancer patients undergoing kidney surgery, to determine the sensitivity and specificity of TLX250-CDx PET imaging to detect clear cell renal cell cancer (ccRCC) in comparison with histologic “standard of truth” determined from surgical resection specimens.